Intercept Pharmaceuticals to Present at the JMP Securities Healthcare
NEW YORK, July 1, 2013
NEW YORK, July 1, 2013 /PRNewswire/ --Intercept Pharmaceuticals, Inc.
(Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused
on the development and commercialization of novel bile acid therapeutics to
treat chronic liver diseases, such as primary biliary cirrhosis, today
announced that Mark Pruzanski, MD, President and Chief Executive Officer, will
present at the JMP Securities 8th Annual Healthcare Conference in New York on
Tuesday, July 9, 2013 at 10:00a.m. ET. A live webcast of the company's
presentation will be available on the "Events" section of Intercept's investor
website at http://ir.interceptpharma.com. A replay of the presentation will
also be archived and available on Intercept's website for 2 weeks.
Intercept is a biopharmaceutical company focused on the development and
commercialization of novel therapeutics to treat orphan and more prevalent
liver diseases, such as primary biliary cirrhosis, utilizing its expertise in
bile acid chemistry. The company's lead product candidate, obeticholic acid
(OCA) is a bile acid analog and first-in-class agonist of the farnesoid X
receptor (FXR). OCA is initially being developed for the second line treatment
of primary biliary cirrhosis (PBC) in patients with an inadequate response to,
or who are unable to tolerate, ursodiol, the only approved therapy for this
indication. OCA has received orphan drug designation in both the United States
and Europe for the treatment of PBC. Intercept owns worldwide rights to OCA
outside of Japan and China, where it has out-licensed the product candidate to
DSP. For more information about Intercept, please visit the Company's website
For more information about Intercept, please contact Mark Pruzanski, M.D., or
Barbara Duncan, both of Intercept Pharmaceuticals, at 1-646-747-1000.
SOURCE Intercept Pharmaceuticals
Press spacebar to pause and continue. Press esc to stop.